Efferon
Agent52Agent Readiness: 52/100. Top 25%. Measured by StartupHub.ai. Median 41.Develops multimodal hemoadsorption therapeutic devices for sepsis and septic shock.
About
Efferon is a biotech company specializing in the development of multimodal hemoadsorption therapeutic devices. Their core technology aims to remove endotoxins and inflammatory mediators directly from the bloodstream. The company's product portfolio includes Efferon LPS, a hemoadsorption cartridge for endotoxin and cytokine adsorption, and Efferon NEO, a version specifically designed for pediatric use.
Key facts
At-a-glance profile data
- Website
- efferon.com
- Headquarters
- Tel Aviv, Israel
- Founded
- 2017
- Total funding
- $18M (Seed)
- Business model
- B2B
Funding rounds
Tech stack
Detected on efferon.com, last scanned 27 Sept 2026. Run your own scan
- Frontend
- Next.js
- CMS / Builders
- Ghost
- CDN
- Vercel
- Email provider
- Google Workspace
Frequently asked
What does Efferon do?
These devices are intended to support faster stabilization of septic shock, reduce time on mechanical ventilation, and decrease intensive care treatment costs. Efferon's platform is also being explored for future applications beyond acute critical illness, targeting chronic and age-related diseases. The company is committed to raising the profile of sepsis treatment globally.
How much funding has Efferon raised?
Efferon has raised a total of $18M in funding. The most recent round on record is Seed.